Launch of Winterlight speech assessmt for academia
Summary by AI BETAClose X
Cambridge Cognition Holdings plc
(“Cambridge Cognition” or the “Company”)
Launch of Winterlight™ speech assessment for academic research
Expanded access to speech-based tools to support wider academic adoption
Cambridge Cognition (AIM: COG), the neuroscience technology company, announces the launch of Winterlight™ speech assessment to academic researchers through the CANTAB Connect Research platform. Researchers can now add Winterlight™ speech tasks alongside CANTAB® touchscreen tasks, questionnaires and scales, enabling complementary and multimodal measures of cognitive performance within a single study. For further information please visit www.cambridgecognition.com/winterlight-for-academic-research.
Winterlight™ has is increasingly used in clinical studies but was, until now, only available to academic researchers through bespoke collaboration agreements. Wider academic use creates opportunities for independent research which expands the evidence base for speech-based biomarkers adding to the more than 3,700 CANTAB® publications. Independent studies establish validity across different populations and settings, which then drives wider use in drug development and healthcare.
Speech provides valuable insights into cognitive function and neuropsychiatric symptoms. A short speech sample can elicit hundreds of measures across acoustic and linguistic features - such as speech rate, pauses, vocabulary and sentence structure - extracting rich data with limited participant burden. Recent academic research has shown that speech also has utility outside neurology and psychiatry in fields as diverse as detecting liver disease.
This launch makes Winterlight™ more readily accessible to the academic market and marks a milestone in Cambridge Cognition’s continued investment in speech with the start of the automatic speech recognition (ASR) project earlier this year. This will strengthen the Company’s leadership in this field and equip researchers, physicians and drug developers with complementary touchscreen and speech-based tools and richer insights.
Rob Baker, CEO of Cambridge Cognition, said:
“Academic researchers play an important role in evaluating new measures and building the independent evidence that supports wider adoption. This launch strengthens both the commercial opportunity for our speech offering and develops its longer-term value in wider applications such as pharmaceutical research and healthcare.”
Dr Sunny X Tang, Associate Professor of Psychiatry, Feinstein Institutes for Medical Research, Northwell Health, commented:
“Speech gives us a practical way to create objective markers for neuropsychiatric conditions which are missing from usual clinical care and clinical trials. In our past work with Cambridge Cognition, we used their speech analysis tool in people with schizophrenia spectrum disorders and found that features, such as speech rate and pauses, track negative symptom severity reliably across visits. In a separate study of 266 participants, a brief speech sample, particularly a simple picture description task, was enough to distinguish people with psychiatric disorders from healthy volunteers with good accuracy.
“These results suggest speech is a promising tool for supporting clinical assessment and screening, even in varied clinical populations where people often have more than one condition. The addition of more independent evidence will further advance this field, validate these tools, and help us better understand where speech measures work best, and how they can be used in research and clinical care.”
ENQUIRIES
|
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer
|
Tel: +44 (0)1223 810 700 |
|
Walbrook PR Limited Anna Dunphy Paul McManus William Turner |
Tel: +44 (0)20 7933 8780 +44 (0)7876 741 001 +44 (0)7980 541 893 +44 (0)7407 020 470 CambridgeCognition@walbrookpr.com
|
|
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith (Corporate Finance) Harriet Ward (Corporate Broking) Nigel Birks (Life Science Specialist Sales)
|
Tel: +44 (0)20 7220 0500
|
|
Singer Capital Markets Limited (Joint Broker) Amber Higgs / Daniel Ingram
|
Tel: +44 (0)20 7496 3000
|
About Cambridge Cognition (www.cambridgecognition.com)
Cambridge Cognition is a neuroscience technology company making brain health measurable at scale. Our validated digital assessments and biomarkers help pharmaceutical sponsors, academic researchers and healthcare providers measure cognitive function accurately and consistently.
Built on more than 40 years of cognitive science, our technologies have been used in over 600 clinical trials and supported more than 3,700 peer-reviewed publications. We combine CANTAB® digital cognitive assessments, Winterlight™ speech and voice biomarkers, electronic clinical outcome assessments, data quality management and specialist scientific services in a scalable platform for clinic-based, hybrid and decentralised studies.
CANTAB Connect Research
CANTAB Connect Research is Cambridge Cognition's self-service platform for academic and non-profit researchers. It gives direct access to the most widely validated digital cognitive assessments in the world.
Researchers can combine touchscreen and voice-based tests with questionnaires and scales, use them in more than 35 languages, and run studies online or offline. CANTAB tests have been validated in more than 3,700 peer-reviewed publications across 250+ indications. The platform helps researchers produce high-quality, reproducible cognitive science quickly and to clinical-grade data standards.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 10 minutes ago LSL Property Services
- 13 minutes ago Bluebird Merchant Ventures (DI)
- 23 minutes ago Power Probe PLC
- 24 minutes ago Origin Enterprises (CDI)
- 40 minutes ago NATWEST GROUP